Physician profile
Syeda Amna Husain
NPI 1629463468
$26,850.92
in general payments reported to CMS, 2019-2025
23 companies · $219 in 2025
The $219 reported for 2025 was more than what 76% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $138 · 2021: $122 · 2022: $306 · 2023: $18K · 2024: $8,342 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $26K · Food and Beverage: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $25,500.00 |
| Food and Beverage | $573.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $25,500.00 | 2023-2024 | Heplisav-B |
| Abbvie INC. | $191.45 | 2019-2025 | |
| Lilly USA, LLC | $159.06 | 2023 | Taltz |
| Janssen Biotech, INC. | $130.39 | 2021-2025 | Tremfya |
| Mayne Pharma Commercial LLC | $122.56 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $114.20 | 2019 | |
| Incyte Corporation | $80.24 | 2021-2022 | |
| Leo Pharma INC. | $70.37 | 2020-2021 | |
| Biofrontera INC. | $70.21 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Abbott Laboratories | $68.64 | 2021-2022 | |
| Epi Health, LLC | $56.74 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $38.19 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $35.84 | 2020-2025 | Cabtreo |
| Ucb, INC. | $35.77 | 2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $29.63 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $23.79 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $22.95 | 2025 | Dupixent |
| Revance Therapeutics, INC. | $20.99 | 2024 | Daxxify |
| Arcutis Biotherapeutics, INC. | $18.76 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $18.20 | 2023 | Camzyos |
| Bioventus LLC | $17.48 | 2022 | |
| Almirall LLC | $14.44 | 2021 | |
| Galderma Laboratories, L.P. | $11.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syeda Amna Husain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.